NewsBenzingaHC Wainwright & Co.维持对Acurx Pharmaceuticals的“买入”评级，将目标价下调至11美元 HC Wainwright & Co.维持对Acurx Pharmaceuticals的“买入”评级，将目标价下调至11美元 Benzinga 2026.11.12 17:21 (GMT+0) Open on Benzinga Other news HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Lowers Price Target to $11 Gold Down 3%; Legence Earnings Top Views Needham Maintains Buy on Wolverine World Wide, Raises Price Target to $26 These Analysts Boost Their Forecasts On Oddity Tech After Upbeat Q3 Results Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses B of A Securities Maintains Underperform on Teekay Tankers, Raises Price Target to $83
